Chronic chagas' heart disease - From pathogenesis to treatment regimes

Applied Cardiopulmonary Pathophysiology

Volumn 16, Issue 1, 2012, Pages 55-81

  Munoz Saravia, Silvia Gilka ^a   Haberland, Annekathrin ^a   Wallukat, Gerd ^a   Schimke, Ingolf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Autoantibodies; Chagas' heart disease; Epidemiology; G protein coupled receptors; Pathogenesis; Treatment; Trypanosoma cruzi

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BENZNIDAZOLE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; MUSCARINIC M2 RECEPTOR; NIFURTIMOX; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ASYMPTOMATIC DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BARIUM MEAL; BLOOD DONOR; BLOOD TRANSFUSION; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CHOLINERGIC SYSTEM; CHRONIC DISEASE; CHRONICITY; CROSS REACTION; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HUMORAL IMMUNITY; MALNUTRITION; MEGACOLON; MEGAESOPHAGUS; MEXICO; MICROANGIOPATHY; MOLECULAR INTERACTION; MOLECULAR MIMICRY; MORTALITY; NERVE INJURY; NONHUMAN; PARASITE CONTROL; PARASITE TRANSMISSION; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; SOUTH AND CENTRAL AMERICA; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT DURATION; TRYPANOSOMA CRUZI; TRYPANOSOMATID INFECTION; UNITED STATES;

EID: 84857936295     PISSN: 09205268     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Moncayo A. Carlos Chagas: Biographical sketch. Acta Trop 2010; 115: 1-4
2. Prata A. Chagas' disease. Infect Dis Clin North Am 1994; 8: 61-76
3. Prata A. Clinical and epidemiological aspects of Chagas disease. The Lancet Infect Dis 2001; 1: 92-100
4. Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas disease. Postgrad Med 2006; 82: 788-798
5. Teixeira AR, Nascimento RJ, Sturm NR. Evolution and pathology in Chagas disease - a review. Mem Inst Oswaldo Cruz 2006; 101: 463-491
6. Marin-Neto JA, Cunha-Nerto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115: 1109-1123
7. Dias JC, Prata A, Correia D. Problems and perspectives for Chagas disease control: in search of realistic analysis. Rev Soc Bras Med Trop 2008; 41: 193-196
8. Salvatella R. Achievements in controlling Chagas disease in Latin America. Conference Geneva (WHO). 2007 July 6
9. Dias JC. Epidemiology of Chagas' disease. In: Wendel S, Brener Z, Camargo ME, Rassi A (Eds). Chagas' Disease (American Trypanosomiasis): its impact on transfusion and clinical medicine. Sao Paulo 2001: Sociedade Brasileira de Hematologia e Hemoterapia; pp. 49-80
10. Dorn PL, Perniciaro L, Yabsley MJ, Roelling DM, Balsamo G, Diaz J, Wesson D. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 2007; 13: 605-607
11. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009; 49: e52-54
12. Guerri-Guttenberg RA, Grana DR, Ambrosio G, Milei J. Chagas cardiomyopathy: Europe is not spared! Eur Heart J 2008; 29: 2587-2591
13. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop 2010; 115: 14-21
14. Schmunis GA. Risk of Chagas disease through transfusions in the Americans. Medicina (B Aires) 1999; 59: 125-134
15. Dias JCP, Schofield CJ. The evolution of Chagas disease (American trypanosomiasis) control after 90 years since Carlos Chagas' discovery. Men Inst Oswaldo Cruz 1999; 94 (suppl. 1): 103-121
16. Centers for Disease Control and Prevention (CDC): Blood donor screening for Chagas disease-United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56: 141-143
17. Piron M, Verges M, Munoz J, Casamitjana N, Sanz S, Maymó RM, Hernández JM, Puig L, Portús M, Gascón J, Sauleda S. Seroprevalence of Trypanosoma cruzi infection in atrisk blood donors in Catalonia (Spain). Transfusion 2008; 48: 1862-1868
18. Guerri-Guttenberg RA, Ciannameo A, Di Girolamo C, Milei JJ. Chagas disease: an emerging public health problem in Italy? Infez Med 2009; 17: 5-13
19. Société de pathologie exotique: Chagas disease. American trypanosomiasis. Recommendation for non-endemic zones. Med Trop (Mars) 2010; 70: 131-132
20. Azogue E. Women and congenital Chagas' disease in Santa Cruz, Bolivia: epidemiological and sociocultural aspects. Soc Sci Med 1993; 37: 503-511
21. Riera C, Guarro A, Kassab HE, Jorba JM, Castro M, Angrill R, Gállego M, Fisa R, Martin C, Lobato A, Portús M. Congenital transmission of Trypanosoma cruzi in Europe (Spain): a case report. Am J Trop Med Hyg 2006; 75: 1078-1081
22. Dias JC, Schofield CJ, Machado EM, Fernandes AJ. Ticks, ivermectin, and experimental Chagas disease. Mem Inst. Oswldo Cruz 2005; 100: 829-832
23. Macedo AM, Machado CR, Oliveira RP, Pena SD. Trypanosoma cruzi: Genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem Inst Oswaldo Cruz 2004; 99: 1-12
24. Manoel-Caetano Fda S, Silva AE. Implications of genetic variability of Trypanosoma cruzi for the pathogenesis of Chagas disease. Cad Saude Publica 2007; 23: 2263-2274
25. Torrico F, Castro M. Enfermedad de Chagas. In: Medicina tropical, CD-Rom, ITGPRESS; 2002; ISBN 90-76070-237
26. Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med parasitol 2006; 100: 663-677
27. Ochs DE, Hnilica VS, Moser DR, Smith JK, Kirchhoff LV. Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi. Am J Trop Med Hyg 1996; 54: 526-529
28. Gironés N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr Top Microbiol Immunol 2005; 296: 89-123
29. Kumar S, Tarleton RL. The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol 1998; 20: 207-216
30. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, Silva JS. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophage in response to live trypomastigotes. Infect Immun 1996; 64: 1961-1967
31. Fresno M, Kopf M, Rivas L. Cytokines and infectious diseases. Immunol Today 1997; 18: 56-58
32. Gazzinelli RT, Oswald IP, Hieny S James SL, Sher A. The microbicidal activity of interferon- gamma-treated macrophages against Trypanosoma cruzi involves an L-argininedependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Eur J Immunol 1992; 22: 2501-2506
33. Munoz-Fernandez MA, Fernandez MA, Fresno M. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol 1992; 22: 301-307
34. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med 1992; 175: 169-174
35. Torrico F, Heremans H, Rivera MT, van Marck E, Billiau A, Carlier Y. Endogenous IFNgamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol 1991; 146: 3626-3632
36. Holscher C, Kohler G, Muller U. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruziinfected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998; 66: 1208-1215
37. Castanos-Velez E, Maerlan S, Osorio LM, Aberg F, Biberfeld P, Orn A, Rottenberg ME. Trypanosoma cruzi infection in tumor necrosis factor receptor p55-deficient mice. Infect Immun 1998; 66: 2960-2968
38. Martin D, Tarleton R. Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunol Rev 2004; 201: 304-317
39. Avila HA, Sigman DS, Cohen LM, Millikan RC, Simpson L (1991) Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas' disease. Mol Biochem Parasitol 48: 211-221
40. Kirchhoff LV, Votava JR, Ochs DE, Moser DR. Comparison of PCR and microscopic methods for detecting Trypanosoma cruzi. J Clin Microbiol 1996; 34: 1171-1175
41. Mady C, de Moraes AV, Galiano N, Décourt LV. Hemodynamic study of the indeterminate form of Chagas' disease. Arq Bras Cardiol 1982; 38: 271-275
42. Sicca RE, Gonzalez Cappa SM, Sanz OP, Mirkin G. Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Bull Soc Pathol Exot 1995; 88: 156-163
43. Lopes ER. Sudden death in patients with Chagas disease. Mem Inst Oswaldo Cruz 1999; 94 (Suppl. 1): 321-324
44. Karp CL, Auwaerter PG. Coinfection with HIV and Tropical Infectious Diseases. I. Protozoal Pathogens. Clin Infect Dis 2007; 45: 1208-1213
45. Andrade LO, Machado CR, Chiari E, Pena SD, Macedo AM. Trypanosoma cruzi: role of host genetic background in the differential tissue distribution of parasite clonal populations. Exp Parasitol 2002; 100: 269-275
46. Tibayrenc M. Human genetic diversity and the epidemiology of parasitic and other transmissible diseases. Adv Parasitology 2007; 64: 377-462
47. Layrisse Z, Fernandez MT, Montagnani S, Matos M, Balbas O, Herrera F, Colorado IA, Catalioti F, Acquatella H. HLA-C*03 is a risk factor for cardiomyopathy in Chagas disease. Human Immunol 2000; 61: 925-929
48. Garcia Borras S, Racca L, Cotorruelo C, Biondi C, Beloscar J, Racca A. Distribution of HLA-DRB1 alleles in Argentinian patients with Chagas' disease cardiomyopathy. Immunol Invest 2009; 38: 268-275
49. Fae KC, Drigo SA, Cunha-Neto E, Ianni B, Mady C, Kalil J, Goldberg AC. HLA and ßmyosin heavy chain do not influence susceptibility to Chagas' disease cardiomyopathy. Microbes and Infection 2000; 2: 745-751
50. Yacoub S, Birks EJ, Slavik Z, Henein M. Early detection of myocardial dysfunction in Chagas disease using novel echocardiographic indices. Trans R Soc Trop Med Hyg 2003; 97: 528-534
51. Dubner S, Schapachnik E, Riera AR, Valero E. Chagas disease: state-of-the-art of diagnosis and management. Cardiol J 2008; 15: 493-504
52. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007; 298: 2171-2181
53. Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, Ruiz Vera B, Armenti H. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90: 655-660
54. Acuatella H. Echocardiography in Chagas heart disease. Circulation 2004; 115: 1124-1131
55. Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies. Top Magn Reson Imaging 2008; 19: 43-57
56. Tanowitz HB, Machado FS, Jelicks LA Shirani J, de Carvalho AC, Spray DC, Factor SM, Kirchhoff LV, Weiss LM. Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). Prog Cardiovasc Dis 2009; 51: 524-539
57. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000; 42: 1571-1561
58. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, Teixeira AR. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000; 63: 111-118
59. Tafuri WL, Maria TA, Lopes ER, Chapadeiro E. Electron microscopy of the myocardium in human trypanosomiasis cruzi. Rev Inst Med Trop Sao Paulo 1973; 15: 347-370
60. Rossi MA. Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis. Med Sci Monit 2001; 7: 820-832
61. Oliveira JS. A natural human model of intrinsic heart nervous system denervation: Chagas' cardiopathy. Am Heart J 1985; 110: 1092-1098
62. Py M, Pedrosa R, Silveira J, Medeiros A, Andre C. Neurological manifestations in Chagas disease without cardiac dysfunction: correlation between dysfunction of the parasympathetic nervous system and white matter lesions in the brain. J Neuroimaging 2009; 19: 332-336
63. Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 2002; 81: 123-132
64. Cunha-Neto E, Bilate AM, Hyland KV Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 2006; 39: 41-54
65. Reis DD, Gazzinelli RT, Gazzinelli G, Colley DG. Antibodies to Trypanosoma cruzi express idiotypic patterns that can differentiate between patients with asymptomatic or severe Chagas' disease. J Immunol 1993; 150: 1611-1618
66. Wallukat G, Nissen E, Müller J, Brinckmann R, Schimke I, Kunze R. The pathophysiological role of autoantibodies directed to Gprotein coupled receptors and therapeutic strategies of antibody removal. In: Brinckmann R, Kunze R (eds) G-protein coupled receptors and autoantibodies. Pabst Science Publishers, 2002; pp. 7-47
67. Masuda MO, Levin M, De Oliveira SF, Dos Santos Costa PC, Bergami PL, Dos Santos Almeida NA, Pedrosa RC, Ferrari I, Hoebeke J, Campos de Carvalho AC. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998; 12: 1551-1558
68. Gouldson PR, Higgs C, Smith RE, Dean MK, Gkoutos GV, Reynolds CA. Dimerization and domain swapping in G-protein-coupled receptors: a computational study. Neuropsychopharmacology 2000; 23: S60-77
69. Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008; 41: 429-433
70. Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myo - cytes. Biomed Biochim Acta 1987; 46: S634-639
71. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64: 97-103
72. Sterin-Borda L, Cossio PM, Gimeno MF, Gimeno AL, Diez C, Laguens RP, Meckert PC, Arana RM: Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects. Cardiovasc Res 1976; 10: 613-622
73. Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin-Borda L. A circulating IgG in Chagas' disease which binds to betaadrenoceptors of myocardium and modulates their activity. Clin Exp Immunol 1984; 57: 679-686
74. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanism underlying dilated cardiomyopathy. Circ J 2009; 73: 602-607
75. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-1429
76. Jahns R, Boivin V, Lohse MJ. Beta 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 2006; 112: 7-14
77. Elies R, Fu LX, Eftekhari P, Wallukat G, Schulze W, Granier C, Hjalmarson A, Hoe beke J. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur J Biochem 1998; 251: 659-666
78. Christ T, Wettwer E, Dobrev D, Adolph E, Knaut M, Wallukat G, Ravens U. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001; 33: 1515-1525
79. Labovsky V, Smulski CR, Gómez K, Levy G, Levin MJ. Anti-beta1-adrenergic receptor autoantibodies with chronic Chagas heart disease. Clin Exp Immunol 2007; 148: 440-449
80. Sterin-Borda L, Perez Leiros C, Wald M, Cremaschi G, Borda E: Antibodies to beta 1 beta 2 adrenoreceptors in Chagas' disease. Clin Exp Immunol 1988; 74: 349-354
81. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J: Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of autoantibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760-2767
82. Krause EG, Bartel S, Beyerdorfer I, Wallukat G. Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-beta 1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy. Blood Press 1996; Suppl 3: 37-40
83. Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, Miller RJ, Jan LY, Lefkowitz RJ, Hamm HE. Molecular basis for interactions of G protein betagamma subunits with effectors. Science 1998; 280: 1271-1274
84. Jane-wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, Clark P, Wang Q, Popovic ZB, Penn MS, Damron DS, Perez DM, Tuohy VK. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007; 116: 399-410
85. Goin JC, Leiros CP, Borda E, Sterin-Borda L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 1997; 11: 77-83
86. Goin JC, Sterin-Borda L, Bilder CR, Varrica LM, Iantorno G, Ríos MC, Borda E. Functional implications of circulatin muscarinic cholinergic receptor autoantibodies in Chagasic patients with achalasia. Gastroenterology 1999; 117: 798-805
87. Sterin-Borda L, Goin JC, Bilder CR, Iantorno G, Hernando AC, Borda E. Interaction of human chagasic IgG with human colon muscarínico acetylcholine receptor: molecular and functional evidence. Gut 2001; 49: 699-705
88. Leiros CP, Sterin-Borda L, Borda ES, Goin JC, Hosey MM. Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. J Biol Chem 1997; 272: 12989-12993
89. Elies R, Ferrari I, Wallukat G, Lebesgue D, Chiale P, Elizari M, Rosenbaum M, Hoebeke J, Levin MJ. Structural and functional analysis of the B cell epitopes recognized by anti- receptor autoantibodies in patients with Chagas' disease. Journal of Immunology 1996; 157: 4203-4211
90. Wallukat G, Nissen E, Morwinski R, Müller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 2000; 25: 261-266
91. Wallukat G, Munoz Saravia GS, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, Diaz Ramirez I, Borges AC, Schimke I. Distinct patterns of autoantibodies against Gprotein- coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010; 55: 463-468
92. Munoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, Diaz Ramirez I, Borges AC, Wallukat G, Schimke I. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010; 56: 526-527
93. Gallerano RH, Marr JJ, Sosa RR. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. Am J Trop Med Hyg 1990; 43: 159-166
94. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009; 7: 157-163
95. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375: 1388-1402
96. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005; 49: 1521-1528
97. Marian-Neto JA, Rassi A Jr; Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S. BENEFIT Investigators Rationale and design of a randomized placebo- controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156: 37-43
98. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran AN, Ghedin E, Worthey EA, Delcher AL, Blandin G, Westenberger SJ, Caler E, Cerqueira GC, Branche C, Haas B, Anupama A, Arner E, Aslund L, Attipoe P, Bontempi E, Bringaud F, Burton P, Cadag E, Campbell DA, Carrington M, Crabtree J, Darban H, da Silveira JF, de Jong P, Edwards K, Englund PT, Fazelina G, Feldblyum T, Ferella M, Frasch AC, Gull K, Horn D, Hou L, Huang Y, Kindlund E, Klingbeil M, Kluge S, Koo H, Lacerda D, Levin MJ, Lorenzi H, Louie T, Machado CR, McCulloch R, McKenna A, Mizuno Y, Mottram JC, Nelson S, Ochaya S, Osoegawa K, Pai G, Parsons M, Pentony M, Pettersson U, Pop M, Ramirez JL, Rinta J, Robertson L, Salzberg SL, Sanchez DO, Seyler A, Sharma R, Shetty J, Simpson AJ, Sisk E, Tammi MT, Tarleton R, Teixeira S, Van Aken S, Vogt C, Ward PN, Wickstead B, Wortman J, White O, Fraser CM, Stuart KD, Andersson B. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005; 15; 309: 409-415
99. Muratore CA, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc Health Risk Manag 2010; 6: 593-601
100. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy - where do we stand after a hundred years? Prog Cardiovasc Dis 2010; 52: 300-316
101. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL Jr, Reis AM, Dantas JB, Ferreira CS, Tavares WC Jr, Rocha MO. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 2007; 153: 544.e1-8
102. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, Souza GE, Bacal F, Bocchi EA. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010; 3: 82-88
103. Sousa, Xavier SS, Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. Arq Bras Cardiol 2008; 91: 306-310
104. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation 1994; 90: 3098-3102
105. Bertolino ND, Villafanha DF, Cardinalli-Neto A, Cordeiro JA, Arcanjo MJ, Theodoropoulos TA, Bestetti RB. Prognostic impact of Chagas' disease in patients awaiting heart transplantation. J Heart Lung Transplant 2010; 29: 449-453
106. Bocchi EA, Fiorelli A. First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology: The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant 2001; 20: 637-645
107. Parra AV, Rodrigues V, Cancella S, Cordeiro JA, Bestetti RB. Impact of socio - economic status on outcome of a Brazilian heart transplant recipients cohort. Int J Cardiol 2008; 125: 142-143
108. Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, Stolf NA. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant 2008; 27: 597-602
109. Moreira LF, Galantier J, Benício A, Leirner AA, Cestari IA, Stolf NA. Left ventricular circulatory support as bridge to heart transplantation in Chagas' disease cardiomyopathy. Artif Organs 2007; 31: 253-258
110. Vilas-Boas F, Feitosa GS, Soares MB, Mota A, Pinho-Filho JA, Almeida AJ, Andrade MV, Carvalho HG, Dourado-Oliveira A, Ribeiro-dos-Santos R. Early results of bone marrow cell transplantation to the myo - cardium of patients with heart failure due to Chagas disease. Arq Bras Cardiol 2006; 87: 159-166
111. Clinical Trials: Cell therapy in Chagas cardiomyopathy 2010 http/www.clinicaltrials.gov/ct2/show/NCT00349271
112. Labovsky V, Smulski CR, Gómez K, Levy G, Levin MJ. Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 2007; 148: 440-449
113. Wallukat G, Reinke P, Dörffel WV, Luther HP, Bestvater K, Felix SB, Baumann G. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996; 54: 191-195
114. Dörffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G, Reinke P. Short-term hemodynamic effect of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994-1997
115. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Döcke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-1598
116. Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-391
117. Schimke I, Müller J, Priem F, Kruse I, Schön B, Stein J, Kunze R, Wallukat G, Hetzer R. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001; 38: 178-783
118. Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347: 1806
119. Schimke I, Müller J, Dandel M, Gremmels HD, Bayer W, Wallukat B, Wallukat G, Hetzer R. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1- adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher 2005; 20: 137-142
120. Dörffel WV, Wallukat G, Dörffel Y, Felix SB, Baumann G. Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol 2004; 97: 529-534
121. Hessel FP, Wegner C, Müller J, Glaveris C, Wasem J. Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Eur J Health Econ 2004; 5: 58-63
122. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Longterm outcome after beta1 adrenoreceptor autoantibody removal in heart transplant candidates with dilated cardiomyopathy. J Am Col Cardiol 2011; 57 (17) Abstr E194
123. Doesch AO, Mueller S, Konstandin M, Celik S, Kristen A, Frankenstein L, Goeser S, Kaya Z, Zugck C, Dengler TJ, Katus HA. Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. J Clin Apher 2010; 25: 315-322
124. Nagatomo Y, Baba A, Ito H, Naito K, Yoshizawa A, Kurita Y, Nakamura I, Monkawa T, Matsubara T, Wakabayashi Y, Ogawa S, Akaishi M, Yoshikawa T. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher 2011; 26: 1-8
125. Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2000; 2: 258-63
126. Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol 2008; 8: 147-152
127. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-257
128. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nature Rev 2010; 9: 537-550
129. Schimke I, Haberland A, Kage A, Wallukat G, Dahmen C. EP2011/060572. Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta1- adrenergic receptor (29.06.2010)
130. Aptamers for treatment and diagnosis of autoantibody based dilated cardiomyopathy (28.07.2010 {pipe} Ref.Nr. 09014) www.ipal.de/t/Life-Science
131. Rönspeck W, Kunze R, Wallukat G. EP 1086955. Peptide gegen DCM hervorrufende Autoantikörper (21.09.1999)
132. Jahns R, Jahns V, Lohse MJ, Palm D. US 2009/0215675: Means for the inhibition of anti-adrenergic receptor antibodies (Aug. 27, 2009)
133. Munoz Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev 2010; [Epub ahead of print]
134. Wallukat G, Podlowski S, Nissen E, Morwinski R, Csonka C, Tosaki A, Blasig IE. Functional and structural characterization of anti-beta1-adrenoceptor autoantibodies of spontaneously hypertensive rats. Mol Cell Biochem 2003; 251: 67-75
135. Nikolaev VO, Boivin V, Störk S, Angermann CE, Ertl G, Lohse MJ, Jahns R. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007; 50: 423-431
136. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649-654
137. Limas CJ, Goldenberg IF, Limas C. Assessment of immune modulation of betaadrenergic pathways in human dilated cardiomyopathy: influence of methodologic factors. Am Heart J 1992; 123: 967-970
138. Del Corsso C, de Carvalho AC, Martino HF, Varanda WA. Sera from patients with idiopathic dilated cardiomyopathy decrease Ca in cardiomyocytes isolated from rabbits. Am J Physiol Heart Circ Physiol 2004; 287: H1928-1936